Skip to content
Lexiscan, Rapiscan(regadenoson)
Lexiscan, Rapiscan (regadenoson) is a small molecule pharmaceutical. Regadenoson was first approved as Lexiscan on 2008-04-10. It has been approved in Europe to treat myocardial perfusion imaging. The pharmaceutical is active against adenosine receptor A2a. In addition, it is known to target adenosine receptor A2b, adenosine receptor A3, and adenosine receptor A1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
diagnosisD003933
Trade Name
FDA
EMA
Lexiscan (generic drugs available since 2022-04-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Regadenoson
Tradename
Company
Number
Date
Products
LEXISCANAstellas PharmaN-022161 RX2008-04-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lexiscan(r) (regadenoson)New Drug Application2020-02-22
regadenosonANDA2022-02-02
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Regadenoson, Lexiscan, Astellas
RE473012027-02-02DP
81061832027-02-02DP
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01E: Other cardiac preparations in atc
C01EB: Other plain cardiac preparations in atc
C01EB21: Regadenoson
HCPCS
Code
Description
J2785
Injection, regadenoson, 0.1 mg
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.136671233
Myocardial ischemiaD017202EFO_1001375I20-I2522115
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9112
AsthmaD001249EFO_0000270J45112
Coronary diseaseD003327112
Hypertrophic cardiomyopathyD002312EFO_0000538I42.111
Heart transplantationD016027EFO_001067311
HypertensionD006973EFO_0000537I1011
Diastolic heart failureD054144EFO_1000899I50.3011
IschemiaD007511EFO_000055611
Show 2 more
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D571214
Heart diseasesD006331EFO_0003777I51.9112
Atrial fibrillationD001281EFO_0000275I48.011
Covid-19D000086382U07.1111
PneumoniaD011014EFO_0003106J18111
Cardiovascular diseasesD002318EFO_0000319I9811
Retinal artery occlusionD015356EFO_1001154H34.111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Magnetic resonance imagingD008279112
GlioblastomaD005909EFO_000051511
AstrocytomaD001254EFO_000027111
OligodendrogliomaD009837EFO_000063111
Healthy volunteers/patients11
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1111
Breast neoplasmsD001943EFO_0003869C5011
Pulmonary hypertensionD006976EFO_0001361I27.2011
Left ventricular dysfunctionD01848711
Sudden death cardiacD016757EFO_000427811
ObesityD009765EFO_0001073E66.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREGADENOSON
INNregadenoson
Description
Regadenoson is a purine nucleoside.
Classification
Small molecule
Drug classadenosine A receptor agonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O
Identifiers
PDB
CAS-ID313348-27-5
RxCUI1546015
ChEMBL IDCHEMBL3989695
ChEBI ID
PubChem CID219024
DrugBankDB06213
UNII ID7AXV542LZ4 (ChemIDplus, GSRS)
Target
Agency Approved
ADORA2A
ADORA2A
Organism
Homo sapiens
Gene name
ADORA2A
Gene synonyms
ADORA2
NCBI Gene ID
Protein name
adenosine receptor A2a
Protein synonyms
adenosine receptor subtype A2a
Uniprot ID
Mouse ortholog
Adora2a (11540)
adenosine receptor A2a (Q60613)
Alternate
ADORA2B
ADORA2B
ADORA3
ADORA3
ADORA1
ADORA1
Organism
Homo sapiens
Gene name
ADORA2B
Gene synonyms
NCBI Gene ID
Protein name
adenosine receptor A2b
Protein synonyms
Uniprot ID
Mouse ortholog
Adora2b (11541)
adenosine receptor A2b (Q8BXI2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,427 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
12,900 adverse events reported
View more details